Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
FAK Inhibitors Market: By Disease Type, By Molecule, By Clinical Phase and Geography
FAK Inhibitors Market: By Disease Type, By Molecule, By Clinical Phase and Geography
FAK (Focal adhesion kinase) Inhibitors Market was valued at US$ xx in 2022 and is poised to grow at a CAGR of x.x% over 2023-2029. A non-receptor tyrosine kinase called focal adhesion kinase (FAK) is involved in the growth, adhesion, migration, and remodeling of the tumor microenvironment (TME), as well as the advancement of most cancer types. Early-stage clinical trials with FAK inhibitors showed them to perform effectively in preclinical settings. Furthermore, strong data suggests that targeting FAK in combination strategies is more successful at reversing the failure of chemotherapies or targeted therapies in solid tumors like metastatic melanoma, non-small cell lung cancer, and pancreatic cancer. According to the American Cancer Society, about 97,610 people will be diagnosed with melanomas in the USA, with around 4% cases of metastatic melanoma according to ASCO. Therefore, the companies are focusing on launching new products to maintain growth in the market. For instance, AB Sciences received FD approval to start phase 3 clinical trials of masitinib for the treatment of progressive multiple sclerosis. The growing prevalence of various types of cancers, greater understanding of the diagnosis, increase in government funding, rising healthcare costs, and increasing adoption of technology also heighten the overall growth of the market.
FAK (Focal adhesion kinase) Inhibitors Market Key Developments:
The market is expected to rise as the incidence of cancer- benign and metastatic has been increasing globally Increased prevalence of cancer such as lymphomas, leukemias, sarcoma, metastatic cancer, and various neoplasms amongst the population is anticipated to grow the market over the forecasting period. Non-small cell lung cancer accounts for 81% of all the lung cancer diagnoses in the USA with an estimated 238,340 adults to be diagnosed with the same in 2023. Therefore, technological advancement, better disease diagnosis, and government screening programs to lower the incidence rate and mortality and increasing medical costs are anticipated to burgeon the growth of the FAK inhibitors market over the forecast years.
FAK inhibitors market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. American market is the highest growing market with many recent developments in cancer therapies. Many drug candidates are awaiting drug approvals from FDA owing to different indications. The Chinese market is another growing market for cancer therapies like FAK inhibitors with many candidates in the pipeline. Therefore, heavy investments in R&D by the companies and a favourable market and the economy are anticipated to burgeon the growth of the FAK inhibitors market over the forecast years.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
By Disease Type |
|
|
By Molecule |
|
|
By Clinical Phase |
|
Download Free Sample Report
The global FAK inhibitors market was valued at US$ xx in 20xx and is expected to grow at x.x% CAGR over the forecast period 20xx – 20xx.
Rising cancer incidence, improving technology with heavy R&D investments in the area are key opportunities for companies to enhance their revenue. over the forecast years
These are used for many indications including leukemias, lymphomas, metastatic melanoma, sarcoma, various types of neoplasms, fibrosis and connective and soft tissue diseases.
AB Science, AstraZeneca, Amplia Therapeutics Ltd., Cancer Therapeutics CRC, Verastem, Inc., 4SC AG, Ascentage Pharma, Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Centaurus Biopharma Ltd., InxMed, Pfizer, Shouyao Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd, Zai Lab
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.